Treatment Options for Recurrent Mycosis Fungoides and the Sézary Syndrome

Treatment of recurrent mycosis fungoides and the Sézary syndrome is usually within a clinical trial and may include the following:

• Radiation therapy to skin lesions or all the skin on the body (TSEB).
• Topical chemotherapy.
• PUVA therapy, to relieve symptoms and improve the quality of life.
• PUVA therapy with biologic therapy (interferon).
• Ultraviolet B (UVB) radiation therapy.
• Topical corticosteroid therapy, to relieve symptoms and improve the quality of life.
• Extracorporeal photochemotherapy.
• Targeted therapy with a radiolabeled monoclonal antibody.
• Targeted therapy with a monoclonal antibody (alemtuzumab or denileukin diftitox).
• Retinoid therapy.
• Chemotherapy.
• High-dose chemotherapy with stem cell transplant.
• Targeted therapy with a histone deacetylase (HDAC) inhibitor (vorinostat or romidepsin).
• A new treatment.

Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with recurrent mycosis fungoides/Sezary syndrome. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. General information about clinical trials is available from the NCI Web site.